AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25999707 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily for one year in the extremely slow/slow EPHX1 enzyme activity group
Number of subjects: 219
Study 25999707 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily for one year in the fast/normal EPHX1 enzyme activity group
Number of subjects: 219
Study 25999707 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) treatment
Number of subjects: 219
Study 22742523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 278
Study 22742523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 21776852 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration anesthesia with primacaine
Number of subjects: 104
Study 19086775 — intervention group
Group type: EXPERIMENTAL
Intervention: SC plus CM
Number of subjects: 393
Study 19086775 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 393
Study 16495262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oritavancin 5 mg/kg/day
Number of subjects: 55
Study 16495262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oritavancin 6.5 mg/kg/day
Number of subjects: 55
Study 16495262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oritavancin 8 mg/kg/day
Number of subjects: 55
Study 16495262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oritavancin 10 mg/kg/day
Number of subjects: 55
Study 16495262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oritavancin
Number of subjects: 55
Study 12626461 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of DEN-specific IgM in saliva
Number of subjects: 147
Study 12626461 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of DEN-specific IgA in serum
Number of subjects: 147
Study 12626461 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of DEN-specific IgA in saliva
Number of subjects: 147
Study 12626461 — intervention group
Group type: COMPARATOR
Intervention: Detection of DEN-specific IgM in serum
Number of subjects: 147
Study 12626461 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of DEN-specific salivary IgM
Number of subjects: 147
Study 11151876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine therapy for 8 weeks
Number of subjects: 20
Study 11151876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine therapy
Number of subjects: 20
Study 9174316 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg epinephrine
Number of subjects: 45
Study 9174316 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg/kg clonidine
Number of subjects: 45
Study 9174316 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/kg 5% meperidine alone
Number of subjects: 45
Study 8249505 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical brush
Number of subjects: 203
Study 8249505 — intervention group
Group type: COMPARATOR
Intervention: Cotton swab
Number of subjects: 203
Study 29750574 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training combined with high-intensity interval training (AT-HIIT)
Number of subjects: 23
Study 29750574 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training combined with high-intensity interval training (RT-HIIT)
Number of subjects: 23
Study 29750574 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 23
Study 27198129 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (LOW) with hemoglobin trigger of 7 g/dL
Number of subjects: 90
Study 27198129 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (HIGH) with hemoglobin trigger of 8 g/dL
Number of subjects: 90
Study 27198129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (LOW and HIGH)
Number of subjects: 90
Study 25555523 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) for 30 minutes every 8 hours starting on postoperative day 1
Number of subjects: 50
Study 25555523 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TENS treatment)
Number of subjects: 50
Study 23733779 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC-wP (Fluorouracil, Doxorubicin, Cyclophosphamide followed by weekly Paclitaxel)
Number of subjects: 1925
Study 23733779 — intervention group
Group type: COMPARATOR
Intervention: FAC (Fluorouracil, Doxorubicin, Cyclophosphamide)
Number of subjects: 1925
Study 23733779 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC-wP
Number of subjects: 1925
Study 23733779 — intervention group
Group type: COMPARATOR
Intervention: FAC
Number of subjects: 1925
Study 20492852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 150
Study 20492852 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 150
Study 20492852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) + SSRI
Number of subjects: 150
Study 19064840 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 170
Study 19064840 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 170
Study 16939737 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hemoglobin transfusion threshold (n = 223)
Number of subjects: 451
Study 16939737 — intervention group
Group type: COMPARATOR
Intervention: High hemoglobin transfusion threshold (n = 228)
Number of subjects: 451
Study 12559680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 385
Study 12559680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 385
Study 12559680 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 385
Study 12559680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 11129765 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized home care intervention provided by advanced practice nurses (APNs) for 4 weeks, including three home visits and five telephone contacts.
Number of subjects: 375
Study 11129765 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up care in an ambulatory setting.
Number of subjects: 375
Study 11129765 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized home care intervention for late stage patients.
Number of subjects: 375
Study 11129765 — intervention group
Group type: COMPARATOR
Intervention: Usual care for late stage patients.
Number of subjects: 375
Study 11129765 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized home care intervention overall.
Number of subjects: 375
Study 11129765 — intervention group
Group type: COMPARATOR
Intervention: Usual care overall.
Number of subjects: 375
Study 9108847 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine combined with oral poliovirus vaccine
Number of subjects: 425
Study 9108847 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC‐5 cell‐derived inactivated poliovirus vaccine as a combined injection
Number of subjects: 425
Study 9108847 — intervention group
Group type: COMPARATOR
Intervention: Live attenuated poliovirus vaccine
Number of subjects: 425
Study 9108847 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (MRC‐5 or Vero cell-derived)
Number of subjects: 425
Study 10149176 — intervention group
Group type: EXPERIMENTAL
Intervention: GSL + Ursodiol (Actigall)
Number of subjects: 661
Study 10149176 — intervention group
Group type: COMPARATOR
Intervention: GSL Only
Number of subjects: 661
Study 4035330 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of amitriptyline (AT) per day
Number of subjects: 12
Study 4035330 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of amitriptyline (AT) per day
Number of subjects: 12
Study 31352795 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg via nasogastric tube after declaration of brain death
Number of subjects: 84
Study 31352795 — intervention group
Group type: COMPARATOR
Intervention: No simvastatin treatment
Number of subjects: 84
Study 29300975 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG + DYG
Number of subjects: 516
Study 29300975 — intervention group
Group type: COMPARATOR
Intervention: hMG + MPA
Number of subjects: 516
Study 27908347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 1292
Study 27908347 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1292
Study 27908347 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP reduction to ≤1,000 pg/ml
Number of subjects: 1292
Study 25386965 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 599
Study 25386965 — intervention group
Group type: COMPARATOR
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 599
Study 22402955 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 15
Study 22402955 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 15
Study 20438009 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (60 minutes, supervised, three times per week for 12 weeks)
Number of subjects: 43
Study 20438009 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (Control group)
Number of subjects: 43
Study 19075279 — intervention group
Group type: EXPERIMENTAL
Intervention: GLSG treatment (1996 to 2004)
Number of subjects: 520
Study 19075279 — intervention group
Group type: COMPARATOR
Intervention: KLSG treatment (1975 to 1986)
Number of subjects: 520
Study 15840776 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally applied fluoride gel (1% sodium fluoride, applied semi-annually)
Number of subjects: 594
Study 12588354 — intervention group
Group type: EXPERIMENTAL
Intervention: Short and intensive chemotherapy (most recent protocol)
Number of subjects: 470
Study 12588354 — intervention group
Group type: COMPARATOR
Intervention: Previous trials (less intensive chemotherapy)
Number of subjects: 470
Study 12588354 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients >= 15 years old
Number of subjects: 470
Study 12588354 — intervention group
Group type: COMPARATOR
Intervention: Patients < 15 years old
Number of subjects: 470
Study 12588354 — intervention group
Group type: EXPERIMENTAL
Intervention: M2/M3 bone marrow involvement
Number of subjects: 470
Study 12588354 — intervention group
Group type: COMPARATOR
Intervention: M1 bone marrow involvement
Number of subjects: 470
Study 12588354 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH >= 500 IU/l
Number of subjects: 470
Study 12588354 — intervention group
Group type: COMPARATOR
Intervention: LDH < 500 IU/l
Number of subjects: 470
Study 10507207 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence
Number of subjects: 15
Study 10507207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nite White
Number of subjects: 15
Study 10507207 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% hydrogen peroxide solution
Number of subjects: 15
Study 8594265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous T(3) (0.8 microg/kg followed by 0.12 microg.kg(‐1).h(‐1) for 6 hours)
Number of subjects: 211
Study 8594265 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (positive control, 5 microg.kg(‐1).min(‐1) for 6 hours)
Number of subjects: 211
Study 8594265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 1768545 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.2 mg sublingually
Number of subjects: 10
Study 1768545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6803191 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nasogastric feedings with phenytoin suspension 300 mg per day
Number of subjects: 25
Study 6803191 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued continuous nasogastric feedings
Number of subjects: 25
Study 6803191 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous tube feedings started with phenytoin suspension 300 mg per day
Number of subjects: 25
Study 6803191 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of phenytoin suspension alone
Number of subjects: 25
Study 30636649 — intervention group
Group type: EXPERIMENTAL
Intervention: Minding the Baby (MTB) intervention
Number of subjects: 0
Study 30636649 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30817597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazhengsan formula (BZSF) and ceftriaxone
Number of subjects: 40
Study 30817597 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone alone
Number of subjects: 40
Study 30817597 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BZSF + ceftriaxone and ceftriaxone alone)
Number of subjects: 40
Study 27939319 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus kefiri LKF01 (DSM32079)
Number of subjects: 20
Study 26519538 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 26519538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24345827 — intervention group
Group type: EXPERIMENTAL
Intervention: LYM‐X‐SORB (LXS)
Number of subjects: 58
Study 24345827 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo comparison supplement
Number of subjects: 58
Study 24345827 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (LXS and placebo)
Number of subjects: 58
Study 21939490 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-tuned imaging (CnTI)
Number of subjects: 150
Study 19512861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric antrum
Number of subjects: 54
Study 19512861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric body
Number of subjects: 54
Study 19512861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric fundus
Number of subjects: 54
Study 17889357 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 95
Study 17889357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 16055263 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine medication for 8 weeks
Number of subjects: 15
Study 16055263 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study 12104059 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 12104059 — intervention group
Group type: COMPARATOR
Intervention: No Amlodipine
Number of subjects: 0
Study 10425807 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% blackcurrant drink (0.49% carbohydrate)
Number of subjects: 24
Study 10425807 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% blackcurrant drink (0.65% carbohydrate)
Number of subjects: 24
Study 10425807 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed citrus drink (4.5% carbohydrate)
Number of subjects: 24
Study 10425807 — intervention group
Group type: COMPARATOR
Intervention: 10% sucrose (control)
Number of subjects: 24
Study 10425807 — intervention group
Group type: COMPARATOR
Intervention: 10% sorbitol (control)
Number of subjects: 24
Study 7589764 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg dihydroergocristine
Number of subjects: 40
Study 7589764 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dihydroergocristine
Number of subjects: 40
Study 7589764 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 2297463 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg BN 52063 p.o.
Number of subjects: 10
Study 2297463 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 mg BN 52063 inhalation
Number of subjects: 10
Study 2297463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2297463 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg BN 52063 p.o. (EIA study)
Number of subjects: 10
Study 2297463 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg BN 52063 inhalation (EIA study)
Number of subjects: 10
Study 6971551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 5000 units daily
Number of subjects: 0
Study 6971551 — intervention group
Group type: COMPARATOR
Intervention: Normal dietary vitamin D
Number of subjects: 0
Study 6971551 — intervention group
Group type: COMPARATOR
Intervention: Diet restricted in vitamin D (less than 50 units)
Number of subjects: 0
Study 31200775 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation (gentle mechanical vibrations administered during 3 h at night for 3 weeks)
Number of subjects: 63
Study 31200775 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo effect controlled using identical instruments)
Number of subjects: 63
Study 31200775 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation
Number of subjects: 63
Study 28732314 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 73
Study 28732314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 25867798 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose Gadolinium (TdGd) administration
Number of subjects: 75
Study 25867798 — intervention group
Group type: EXPERIMENTAL
Intervention: Less frequent gadolinium administration
Number of subjects: 75
Study 24112999 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine IR, 150 mg
Number of subjects: 6
Study 24112999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 21377076 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA group with continuous background morphine infusion (Group 2; n = 30)
Number of subjects: 60
Study 21377076 — intervention group
Group type: COMPARATOR
Intervention: PCA group without continuous background morphine infusion (Group 1; n = 30)
Number of subjects: 60
Study 21377076 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 19289979 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment by community health workers (CHWs) using injectable antibiotics for very severe disease.
Number of subjects: 8474
Study 19289979 — intervention group
Group type: COMPARATOR
Intervention: Treatment by qualified medical providers.
Number of subjects: 8474
Study 19289979 — intervention group
Group type: COMPARATOR
Intervention: No treatment or treatment by unqualified providers.
Number of subjects: 8474
Study 19289979 — intervention group
Group type: COMPARATOR
Intervention: Home treatment by CHWs compared to no treatment/untrained providers.
Number of subjects: 8474
Study 19289979 — intervention group
Group type: COMPARATOR
Intervention: Treatment by qualified providers compared to no treatment/untrained providers.
Number of subjects: 8474
Study 19289979 — intervention group
Group type: COMPARATOR
Intervention: Neonates with convulsions.
Number of subjects: 8474
Study 19289979 — intervention group
Group type: COMPARATOR
Intervention: Neonates with chest in-drawing.
Number of subjects: 8474
Study 19289979 — intervention group
Group type: COMPARATOR
Intervention: Neonates with temperature <35.3 degrees C.
Number of subjects: 8474
Study 19289979 — intervention group
Group type: COMPARATOR
Intervention: Neonates with unconsciousness.
Number of subjects: 8474
Study 18065585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3 g/d, 1.8 g n-3 PUFAs)
Number of subjects: 27
Study 18065585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (paraffin oil)
Number of subjects: 27
Study 15367054 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 21
Study 15367054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 21
Study 15367054 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer and partner support
Number of subjects: 21
Study 15367054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective counseling
Number of subjects: 21
Study 15367054 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation/massage therapy
Number of subjects: 21
Study 15367054 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant sleep interventions
Number of subjects: 21
Study 15367054 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant-mother relationship therapy
Number of subjects: 21
Study 15367054 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exercise
Number of subjects: 21
Study 10706235 — intervention group
Group type: EXPERIMENTAL
Intervention: Kudzu root extract 1.2 g twice daily
Number of subjects: 38
Study 10706235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9305414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin 2.5 mg
Number of subjects: 15
Study 9305414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin 10 mg
Number of subjects: 15
Study 9305414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9305414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (both doses)
Number of subjects: 15
Study 1467416 — intervention group
Group type: EXPERIMENTAL
Intervention: Trometamol Phosphomicine (TP) - single oral dose
Number of subjects: 150
Study 1467416 — intervention group
Group type: COMPARATOR
Intervention: Pipemidic Acid (PA) - 400 mg twice a day for 5 to 7 days
Number of subjects: 150
Study 1467416 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacine (NFX) - 400 mg twice a day for 5 to 7 days
Number of subjects: 150
Study 6096241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 36
Study 6096241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29578169 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy
Number of subjects: 76
Study 29578169 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 76
Study 27026584 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing plus audit and feedback
Number of subjects: 0
Study 27026584 — intervention group
Group type: COMPARATOR
Intervention: Audit and feedback alone
Number of subjects: 0
Study 1424409 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo after 50 mg atenolol daily
Number of subjects: 24
Study 1424409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1424409 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24